# FORM 2
THE PATENTS ACT, 1970
(39 of 1970)
&
THE PATENTS RULES, 2003

## COMPLETE SPECIFICATION
(See Section 10 and Rule 13)

---

### 1. TITLE OF THE INVENTION
**A NON-INVASIVE WEARABLE PHYSIOLOGICAL SENSOR APPARATUS AND MULTI-COMPARTMENT DIGITAL TWIN SYSTEM FOR CONTINUOUS CUFFLESS HEMODYNAMIC-METABOLIC EXCURSION FORECASTING AND CLOSED-LOOP SKELETAL GLUCOSE CLEARANCE CONTROL**

---

### 2. APPLICANT(S)
* **Name:** BioSync AI Systems India Private Limited
* **Nationality:** Indian
* **Address:** Cyber Pearl, Hitech City, Hyderabad, Telangana 500081, India

---

### 3. PREAMBLE TO THE DESCRIPTION
The following specification particularly describes the invention and the manner in which it is to be performed.

---

### 4. FIELD OF THE INVENTION
The present invention relates generally to biomedical informatics, wearable hemodynamic sensor engineering, and computational biophysical transport modeling. More particularly, the present invention relates to a non-invasive wearable physiological sensor apparatus and closed-loop biofeedback control system that:
1. Samples raw optical photoplethysmography (PPG) waveforms and electrocardiogram (ECG) telemetry to derive continuous arterial Pulse Transit Time (PTT);
2. Computes continuous cuffless blood pressure via calibrated differential Hughes non-linear vascular elastance and Moens-Korteweg wave propagation equations;
3. Classifies jaw mastication frequencies ($1.2\text{ to }2.5\text{ Hz}$) via acoustic and 3-axis accelerometer sensor arrays to autonomously detect meal-ingestion start events;
4. Dynamically calibrates patient-specific physiological baseline parameters via authenticated HL7 FHIR R4 care-context integration with the Ayushman Bharat Digital Mission (ABDM) national health infrastructure;
5. Simulates 4-hour postprandial glycemic transport trajectories $G(t)$ and hemodynamic load $\text{BP}(t)$ using a 7-compartment Runge-Kutta fourth-order Ordinary Differential Equation (ODE) solver accounting for grain-specific amylose linear chains, retrograded type-3 resistant starch (RS3) crystal structures, and dietary lipid gastric delay; and
6. Autonomously calculates and enforces a closed-loop skeletal muscle glucose transporter-4 (GLUT-4) ambulation step burn protocol to physically clear surplus vascular glucose mass prior to hepatic overflow.

---

### 5. BACKGROUND OF THE INVENTION & PRIOR ART
Type-2 Diabetes Mellitus (T2D), metabolic syndrome, and essential hypertension constitute a compounding non-communicable disease burden across India and the developing world. The Indian population exhibits a distinct phenotype—often referred to as the "Thin-Fat Indian" or South Asian metabolic phenotype—characterized by higher visceral adiposity, severe insulin resistance at lower Body Mass Index (BMI), lower skeletal muscle mass, and pronounced postprandial glycemic excursions following carbohydrate-rich traditional diets (e.g. polished white rice, refined wheat flour flatbreads, and fried snacks).

Conventional approaches to postprandial glucose management suffer from critical structural drawbacks:
1. **Lagging Continuous Glucose Monitors (CGM):** Commercial interstitial needle sensors measure glucose in interstitial fluid rather than vascular blood, introducing a biological lag time of 10 to 25 minutes. Consequently, by the time a CGM sounds a high-glucose alert (e.g. $>180\text{ mg/dL}$), the physiological glucose surge has already peaked, vascular endothelial oxidative stress has occurred, and cellular damage is underway.
2. **Absence of Biophysical Digestion Kinetics:** Existing consumer health software relies on rudimentary static calorie counters or empirical point heuristics. They fail to mathematically account for the differential hydrolysis rates of starches (amylose linear $\alpha\text{-(1}\rightarrow\text{4)}$ chains versus amylopectin branched $\alpha\text{-(1}\rightarrow\text{6)}$ chains), the enzymatic inhibition induced by retrograded type-3 resistant starch (RS3), gastric delay induced by dietary lipids, or the physical barrier effects of viscous soluble fibers coating intestinal mucosal villi.
3. **Decoupling of Glycemia and Hemodynamics:** Dietary sodium, postprandial hyperinsulinemia, and autonomic tone fluctuations induce substantial postprandial blood pressure surges. Existing platforms track glucose and blood pressure in complete isolation, ignoring the coupling between arterial stiffness, pulse wave velocity, and vascular shear stress.
4. **Lack of Autonomous Physical Mitigation:** Conventional apps provide passive text advice ("Try to walk tomorrow"). They lack a real-time mathematical translation layer that computes the exact mass of dietary glucose surplus in grams and translates that mass into an immediate, physical ambulatory exercise prescription (cadence, duration, and step count) required to clear the surplus via insulin-independent skeletal muscle GLUT-4 translocation before hepatic overflow occurs.
5. **Fragmentation from National Health Infrastructure:** Existing wearable platforms do not interoperate with statutory national electronic health records, leading to uncalibrated simulations that ignore verified hospital laboratory biomarkers (e.g. HbA1c, eGFR, lipid panel).

Accordingly, there exists an acute unmet technical need for a closed-loop biophysical system and sensor apparatus that bridges real-time wearable hemodynamics, ABDM-linked laboratory calibration, and mathematical multi-compartment digestion transport kinetics to predict and physically mitigate metabolic excursions in real time.

---

### 6. COMPLIANCE WITH SECTION 3(k), SECTION 3(i), AND INDIAN PATENT JURISPRUDENCE
The present invention does not constitute a "computer program per se", a "mathematical algorithm", or a "method of treatment" under Section 3(k) or Section 3(i) of the Indian Patents Act, 1970. Under the landmark jurisprudence established by the Hon'ble High Court of Delhi in *Ferid Allani v. Union of India (2019)*, *Telefonaktiebolaget LM Ericsson v. Intex Technologies (2015)*, and *Microsoft Corporation v. Commissioner of Patents (2023)*, as well as the Guidelines for Examination of Computer-Related Inventions (CRI, 2017) issued by the Indian Patent Office:
1. **Tangible Physical Transformation:** The invention operates directly upon physical optical signals (PPG infrared/red photodiode currents) and acoustic/inertial sensor voltages, physically transforming raw millivolt waveform signals into pulse transit times, arterial wall elastance metrics, and mastication frequency bands.
2. **Technical Effect Outside the Computer:** The system controls a real-world physical and physiological process: specifically, the targeted mechanical ambulation of skeletal muscle tissue to trigger non-insulin-mediated glucose transporter-4 (GLUT-4) membrane translocation, thereby altering the actual physical chemical concentration of glucose within the patient's circulating vascular system.
3. **Hardware Coupling & Sensor Actuators:** The claims explicitly recite specific physical hardware components, including multi-wavelength optical PPG sensors, 3-axis inertial measurement units, acoustic transducers, microcontrollers, wireless transceivers, and closed-loop biofeedback actuators.
4. **Non-Therapeutic Control System (Section 3(i) Compliance):** The claimed system is an automated biofeedback actuator and physical ambulation cadence regulator that guides voluntary mechanical muscular exertion, rather than a method of surgical, curative, or diagnostic treatment practiced directly on the human body.

---

### 7. SUMMARY OF THE INVENTION
The present invention provides a unified biophysical digital twin computing architecture and wearable sensor apparatus configured to perform real-time metabolic forecasting and closed-loop physical ambulation control.

In accordance with a first aspect of the present invention, a physical wearable sensing unit captures continuous optical photoplethysmogram (PPG) waveforms and inertial signals. A calibrated differential Moens-Korteweg and Hughes elasticity estimator converts pulse transit time (PTT) into continuous cuffless systolic and diastolic blood pressure. Heart Rate Variability (HRV) time-domain analysis computes Root Mean Square of Successive Differences (RMSSD) and Baevsky Stress Index to continuously track sympathovagal autonomic tone.

In accordance with a second aspect of the present invention, an acoustic and inertial classifier monitors jaw mastication frequencies ($1.2\text{ to }2.5\text{ Hz}$) to autonomously trigger meal-start digital twin simulation without requiring manual user data entry.

In accordance with a third aspect of the present invention, the system establishes a secure, end-to-end encrypted connection with the Ayushman Bharat Digital Mission (ABDM) national gateway, retrieving authenticated HL7 FHIR R4 DiagnosticReports (LOINC `1558-6` Fasting Glucose, LOINC `4548-4` HbA1c, LOINC `33914-3` eGFR) to dynamically calibrate patient-specific baseline glucose distribution volume $V_G$, resting clearance time constant $\tau_{\text{clearance}}$, and peripheral insulin sensitivity $S_I$.

In accordance with a fourth aspect of the present invention, a 7-compartment Ordinary Differential Equation (ODE) Runge-Kutta fourth-order solver models the biophysical transport of ingested nutrients:
* Compartment 1 ($q_{\text{sto1}}$): Solid stomach phase (mechanical mastication grinding).
* Compartment 2 ($q_{\text{sto2}}$): Liquid stomach phase (gastric emptying under lipid and volume feedback).
* Compartment 3 ($q_{\text{gut}}$): Duodenal and proximal jejunal lumen (hydrolysis of digestible carbohydrates).
* Compartment 4 ($q_{\text{portal}}$): Hepatic portal delivery.
* Compartment 5 ($G(t)$): Plasma glucose concentration.
* Compartment 6 ($X(t)$): Dynamic interstitial insulin action.
* Compartment 7 ($\text{BP}(t)$): Arterial volume-sodium vascular load.

The starch absorption rate constant $k_{\text{abs}}$ is dynamically modulated by the amylose-to-amylopectin ratio ($\alpha_{\text{amylose}}$) and retrograded resistant starch factor ($\beta_{\text{RS3}}$):
$$k_{\text{abs}} = k_{\text{abs0}} \cdot (1.0 - 0.45 \cdot \alpha_{\text{amylose}}) \cdot (1.0 - 0.60 \cdot \beta_{\text{RS3}}) \cdot \kappa_{\text{viscosity}}$$

In accordance with a fifth aspect of the present invention, whenever the ODE trajectory forecasts a glycemic peak exceeding the patient's individual clinical ceiling ($G_{\max} > G_{\text{threshold}}$), the system computes the exact excess mass of circulating glucose ($m_{\text{excess}}$) and calculates an autonomous postprandial ambulation prescription:
$$\text{WalkMinutes} = \text{round}\left(\frac{m_{\text{excess}}}{0.38\text{ g/min}} \times 1.35\right)$$
$$\text{TargetSteps} = \text{WalkMinutes} \times 110\text{ steps/min}$$
The wearable sensor streams live step telemetry and acoustic cadence back to the controller, confirming skeletal muscle GLUT-4 glucose clearance in real time.

---

### 8. BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS
The invention is illustrated in the accompanying drawings:
* **FIG. 1** illustrates the overall system architecture, sensor signal conditioning stage, and communication flow between the physical wearable hardware and the biophysical ODE engine.
* **FIG. 2** depicts the calibrated Moens-Korteweg and Hughes differential elasticity model for cuffless blood pressure and pulse wave velocity (PWV) derivation from Pulse Transit Time (PTT).
* **FIG. 3** illustrates the 7-compartment biophysical Runge-Kutta fourth-order transport block diagram from gastric mastication to peripheral tissue uptake.
* **FIG. 4** shows the enzymatic hydrolysis retardation curves illustrating the damping effect of amylose ratio and retrograded resistant starch (RS3) on glucose rate of appearance ($Ra(t)$).
* **FIG. 5** illustrates the skeletal muscle GLUT-4 translocation biofeedback control loop and mathematical step-count burn derivation.
* **FIG. 6** depicts the 3-phase pre-bite mucosal coating sequencing protocol for intestinal $\alpha$-amylase inhibition.
* **FIG. 7** is a comprehensive flowchart illustrating the autonomous closed-loop digital twin execution, acoustic meal-start detection, ABDM FHIR R4 calibration, and live step-count reconciliation.

---

### 9. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Referring now to the drawings in detail, and particularly to **FIG. 1**, the system comprises a physical wearable sensor apparatus (100) communicatively coupled via an encrypted Bluetooth Low Energy (BLE 5.3) or Cellular IoT transceiver (106) to a biophysical processing host (200).

#### A. Sensor Signal Conditioning & Hemodynamic Estimator
The wearable sensor apparatus (100) incorporates a multi-wavelength reflective optical photoplethysmography (PPG) sensor (101) operating at $660\text{ nm}$ (red) and $940\text{ nm}$ (infrared) wavelengths, an integrated single-lead electrocardiogram (ECG) analog front-end (102), and a 3-axis digital accelerometer/inertial measurement unit (103).

A bandpass Butterworth analog filter (104) having a passband between $0.5\text{ Hz}$ and $5.0\text{ Hz}$ conditions the raw photodiode current, removing baseline respiratory wander and high-frequency motion artifacts. The analog-to-digital converter (105) samples the filtered signal at $250\text{ Hz}$.

The processing unit measures the time elapsed between the ventricular depolarization R-wave peak on the ECG waveform (102) and the arrival of the systolic inflection point of the peripheral PPG pulse wave at the radial artery (101). This time differential defines the Pulse Transit Time ($\text{PTT}$, expressed in milliseconds).

Under the classical Moens-Korteweg equation, Pulse Wave Velocity ($\text{PWV}$) through an elastic arterial conduit is defined by:
$$\text{PWV} = \frac{L}{\text{PTT}} = \sqrt{\frac{E \cdot h}{2 R \cdot \rho}}$$
where $L$ is the arterial vessel length from aortic root to peripheral sensor site, $E$ is Young's modulus of arterial elasticity, $h$ is vessel wall thickness, $R$ is resting arterial lumen radius, and $\rho$ is human blood density ($\approx 1060\text{ kg/m}^3$).

Young's modulus $E$ increases exponentially with transmural blood pressure $P$ in accordance with the Hughes elasticity relationship:
$$E(P) = E_0 \cdot e^{\gamma \cdot P}$$
where $E_0$ is zero-pressure elasticity, and $\gamma$ is a patient-specific vascular stiffening coefficient (nominally $0.024\text{ mmHg}^{-1}$).

To prevent systemic drift and numerical clipping, the system derives differential Systolic Blood Pressure ($\Delta \text{SBP}$) relative to a nominal resting calibration baseline ($\text{PTT}_0 = 220\text{ ms}$, $\text{SBP}_0 = 120\text{ mmHg}$):
$$\text{SBP}(t) = \text{SBP}_0 + \frac{2}{\gamma} \ln\left(\frac{\text{PTT}_0}{\text{PTT}(t)}\right) + \kappa_{\text{HR}} \cdot (\text{HR}(t) - \text{HR}_0)$$
$$\text{DBP}(t) = \text{SBP}(t) \cdot \left[0.66 - 0.001 \cdot (\text{SBP}(t) - 120)\right]$$
where $\kappa_{\text{HR}}$ is an autonomic heart-rate coupling factor ($\approx 0.08\text{ mmHg/bpm}$).

Simultaneously, the processing unit extracts inter-beat intervals (RR intervals) from the ECG/PPG stream to calculate Heart Rate Variability (HRV). Root Mean Square of Successive Differences (RMSSD) is derived over a sliding 3-minute window:
$$\text{RMSSD} = \sqrt{\frac{1}{N - 1} \sum_{i=1}^{N-1} (RR_{i+1} - RR_i)^2}$$
Baevsky's Stress Index ($SI$) is computed from the modal amplitude ($AMo$), mode ($Mo$), and variation range ($MxDMn$) of the RR histogram:
$$SI = \frac{AMo}{2 \cdot Mo \cdot MxDMn}$$
A value of $SI > 250$ indicates intense sympathetic autonomic arousal, which the ODE solver utilizes to increase endogenous hepatic glucose production ($EGP$) and induce acute transient insulin resistance.

#### B. Autonomous Acoustic & Inertial Meal-Start Detector
The 3-axis accelerometer (103) and wrist skin-contact microphone capture high-frequency inertial tremors and acoustic transients during eating. The signal is passed through a discrete bandpass filter centered on the human mastication frequency band ($1.2\text{ to }2.5\text{ Hz}$). A rolling energy envelope and zero-crossing density classifier detects repetitive chew-swallow cycles lasting $\ge 180\text{ seconds}$ with confidence metric $>0.85$. Upon confirmation, the system automatically initializes the 7-compartment digital twin ODE engine without requiring the user to launch a mobile application.

#### C. Interoperability with Ayushman Bharat Digital Mission (ABDM) & Calibration
The biophysical host (200) interfaces with the National Health Authority (NHA) ABDM Gateway:
1. Validates the patient's authenticated 14-digit ABHA ID (`91-XXXX-XXXX-XXXX`) via Aadhaar/Mobile OTP (Milestone M1).
2. Requests consent artefacts (Milestone M3) to ingest authenticated HL7 FHIR R4 DiagnosticReport resources from certified hospital clinical laboratories.
3. Automatically extracts standardized LOINC biomarkers: Fasting Plasma Glucose (`1558-6`), Glycated Hemoglobin HbA1c (`4548-4`), Estimated Glomerular Filtration Rate eGFR (`33914-3`), and Systolic Blood Pressure (`8480-6`).
4. Calibrates the digital twin ODE parameters:
   * Dynamic insulin sensitivity factor $S_I$ is scaled inversely with HbA1c: $S_I = S_{I0} \cdot (5.4 / \text{HbA1c})$.
   * Renal glucose clearance threshold $G_{\text{renal}}$ is adjusted based on eGFR ($180\text{ mg/dL}$ normal; down-regulated to $150\text{ mg/dL}$ in Stage 3 CKD to prevent tubular overload).
   * Baseline vascular volume $V_G$ is calibrated to lean body mass derived from hospital bioimpedance or clinical metrics.

#### D. 7-Compartment Biophysical Runge-Kutta ODE Solver
Referring to **FIG. 3**, the digestion and assimilation of dietary nutrients are governed by a 7-compartment mathematical system solved continuously across a 240-minute simulation grid using a 4th-order Runge-Kutta (RK4) numerical integrator with fixed step size $\Delta t = 1.0\text{ minute}$.

The system variables represent:
* $q_{\text{sto1}}(t)$: Solid carbohydrate mass in the stomach (grams).
* $q_{\text{sto2}}(t)$: Liquid/chyme carbohydrate mass in the stomach (grams).
* $q_{\text{gut}}(t)$: Glucose mass within the intestinal lumen (grams).
* $Ra(t)$: Rate of glucose appearance into the hepatic portal circulation (mg/dL/min).
* $G(t)$: Plasma glucose concentration in systemic circulation (mg/dL).
* $X(t)$: Remote interstitial insulin activity ($\text{min}^{-1}$).
* $I(t)$: Systemic plasma insulin concentration ($\mu\text{U/mL}$).

The governing transport equations are defined as:
$$\frac{dq_{\text{sto1}}}{dt} = -k_{\text{gri}} \cdot q_{\text{sto1}}$$
$$\frac{dq_{\text{sto2}}}{dt} = k_{\text{gri}} \cdot q_{\text{sto1}} - k_{\text{empt}}(t) \cdot q_{\text{sto2}}$$
where $k_{\text{gri}}$ is the gastric grinding breakdown constant ($0.045\text{ min}^{-1}$).

The gastric emptying rate $k_{\text{empt}}(t)$ is dynamically regulated by the lipid content ($M_{\text{fat}}$, grams) and total meal caloric volume:
$$k_{\text{empt}}(t) = k_{\text{empt0}} \cdot \left[1.0 + 0.35 \cdot \tanh\left(\frac{M_{\text{fat}}}{25.0}\right)\right]^{-1}$$
High dietary fat delays gastric emptying, flattening and broadening the postprandial glycemic surge.

Within the intestinal compartment, the rate of enzymatic hydrolysis by pancreatic $\alpha$-amylase and brush-border $\alpha$-glucosidase to yield free absorbable glucose is governed by:
$$\frac{dq_{\text{gut}}}{dt} = k_{\text{empt}}(t) \cdot q_{\text{sto2}} - k_{\text{abs}} \cdot q_{\text{gut}}$$

Crucially, the starch absorption coefficient $k_{\text{abs}}$ is formulated as a biophysical function of grain molecular architecture:
$$k_{\text{abs}} = k_{\text{abs0}} \cdot \left(\frac{\text{GI}}{55.0}\right) \cdot (1.0 - 0.45 \cdot \alpha_{\text{amylose}}) \cdot (1.0 - 0.60 \cdot \beta_{\text{RS3}}) \cdot (1.0 - \kappa_{\text{fiber}})$$
where:
* $\text{GI}$ is the food item's Glycemic Index.
* $\alpha_{\text{amylose}}$ is the amylose mass fraction of total starch (ranging from $0.10$ for waxy grains to $0.35$ for aged Basmati or parboiled pulses).
* $\beta_{\text{RS3}}$ is the type-3 retrograded resistant starch factor ($0.00$ to $0.30$), formed by gelatinization followed by cooling crystallization.
* $\kappa_{\text{fiber}} = \min(0.35, M_{\text{fiber}} / 40.0)$ is the physical boundary diffusion barrier created by soluble dietary fiber.

The rate of glucose appearance into systemic vascular volume is:
$$Ra(t) = \frac{f \cdot k_{\text{abs}} \cdot q_{\text{gut}}(t) \cdot 1000}{V_G \cdot BW}$$
where $f$ is fractional absorption bioavailability ($0.88$), $V_G$ is distribution volume ($1.7\text{ dL/kg}$), and $BW$ is patient body weight in kilograms.

Systemic plasma glucose $G(t)$ is modeled by the coupled differential system:
$$\frac{dG}{dt} = Ra(t) - (S_G + X(t)) \cdot G(t) + S_G \cdot G_b - \text{GLUT4}_{\text{exercise}}(t)$$
$$\frac{dX}{dt} = -p_2 \cdot X(t) + p_3 \cdot (I(t) - I_b)$$
where $S_G$ is glucose effectiveness ($0.014\text{ min}^{-1}$), $G_b$ is basal euglycemic glucose ($90\text{ mg/dL}$), $p_2$ is interstitial insulin clearance rate ($0.025\text{ min}^{-1}$), and $p_3$ is insulin action transudation coefficient.

#### E. Skeletal Muscle GLUT-4 Ambulation Mitigation Protocol
Referring to **FIG. 5**, when simulated postprandial trajectory projects a peak glucose excursion exceeding the clinical target ($G_{\max} > 140\text{ mg/dL}$), the engine computes the integrated area under the curve above threshold:
$$\text{AUC}_{\text{excess}} = \int_{0}^{240} \max(0, G(t) - 140) \, dt \quad (\text{mg}\cdot\text{min/dL})$$
The surplus circulating glucose mass to be cleared is derived as:
$$m_{\text{excess}} = \frac{\text{AUC}_{\text{excess}} \cdot V_G \cdot BW}{1000 \cdot \tau_{\text{clearance}}} \quad (\text{grams})$$

Skeletal muscle contraction during ambulation promotes 5'-AMP-activated protein kinase (AMPK) phosphorylation, causing the mechanical translocation of GLUT-4 storage vesicles to the skeletal sarcolemma membrane *entirely independent of insulin receptor signaling*.

The rate of skeletal muscle glucose clearance per minute of brisk walking ($4.5\text{ km/h}$, cadence $110\text{ steps/min}$) in human adults is approximately $0.38\text{ g/min}$. Incorporating a biophysical safety factor of $1.35$ to account for ongoing hepatic glycogenolysis:
$$\text{WalkMinutes} = \text{round}\left(\frac{m_{\text{excess}}}{0.38} \times 1.35\right)$$
$$\text{TargetSteps} = \text{WalkMinutes} \times 110$$

The engine defines a physiological start window:
$$t_{\text{start}} = \max\left(20, t_{\text{peak}} - 20\right) \quad (\text{minutes post-meal})$$
Initiating ambulation 20 minutes prior to the projected glucose peak intercepts the rapid ascending inflection point ($\frac{dG}{dt} > 0$), blunting the maximum peak surge by up to $38\%$.

The wearable accelerometer (103) streams live step counts back to the service. The service updates remaining surplus glucose in real time:
$$m_{\text{remaining}}(t) = \max\left(0, m_{\text{excess}} - \left[\frac{\text{StepsCompleted}(t)}{110} \times 0.38 \times \frac{1}{1.35}\right]\right)$$
Upon reaching $100\%$ target fulfillment, the wearable actuator triggers a distinct haptic pulse confirming metabolic stabilization.

---

### 10. CLAIMS

**WE CLAIM:**

1. A biophysical simulation system for real-time postprandial metabolic forecasting and closed-loop physical ambulation control, the system comprising:
   * a physical wearable device (100) comprising at least one optical photoplethysmography (PPG) sensor (101), an inertial measurement unit (103), an acoustic sensor, a microprocessor, and a wireless transceiver (106);
   * a hemodynamic estimation engine executed by at least one hardware processor, configured to sample raw optical PPG waveforms and compute a continuous Pulse Transit Time (PTT) metric;
   * a multi-compartment Ordinary Differential Equation (ODE) digital twin engine configured to simulate postprandial glycemic transport $G(t)$ across a continuous multi-hour time domain by numerically integrating gastric emptying, duodenal enzymatic starch hydrolysis, and tissue uptake; and
   * an autonomous biofeedback ambulation controller configured to evaluate said glycemic transport $G(t)$ against a predetermined clinical ceiling $G_{\text{threshold}}$, compute a surplus circulating glucose mass $m_{\text{excess}}$, calculate a target physical step count, and track mechanical step telemetry streamed from said wearable device to confirm glucose oxidation via skeletal muscle glucose transporter-4 (GLUT-4) translocation.

2. The system as claimed in claim 1, wherein said hemodynamic estimation engine derives continuous cuffless Systolic Blood Pressure ($\text{SBP}$) from Pulse Transit Time ($\text{PTT}$) using a calibrated differential Hughes elasticity equation:
   $$\text{SBP}(t) = \text{SBP}_0 + \frac{2}{\gamma} \ln\left(\frac{\text{PTT}_0}{\text{PTT}(t)}\right) + \kappa_{\text{HR}} \cdot (\text{HR}(t) - \text{HR}_0)$$
   wherein $\text{PTT}_0$ is a nominal calibration pulse transit time, $\text{SBP}_0$ is a baseline systolic pressure, $\gamma$ is a vascular stiffening parameter, $\text{HR}(t)$ is instantaneous heart rate, and $\kappa_{\text{HR}}$ is an autonomic coupling coefficient.

3. The system as claimed in claim 1, wherein said multi-compartment ODE engine integrates a 7-compartment transport model comprising:
   * a solid-phase gastric compartment ($q_{\text{sto1}}$);
   * a liquid-phase gastric compartment ($q_{\text{sto2}}$);
   * an intestinal duodenal lumen compartment ($q_{\text{gut}}$);
   * an intestinal starch hydrolysis rate constant $k_{\text{abs}}$;
   * an interstitial insulin action compartment ($X(t)$);
   * a vascular blood glucose compartment ($G(t)$); and
   * a vascular hemodynamic blood pressure load compartment ($\text{BP}(t)$).

4. The system as claimed in claim 3, wherein said intestinal starch hydrolysis rate constant $k_{\text{abs}}$ is formulated as an inverse function of dietary amylose ratio ($\alpha_{\text{amylose}}$) and retrograded type-3 resistant starch factor ($\beta_{\text{RS3}}$):
   $$k_{\text{abs}} = k_{\text{abs0}} \cdot \left(\frac{\text{GI}}{55.0}\right) \cdot (1.0 - 0.45 \cdot \alpha_{\text{amylose}}) \cdot (1.0 - 0.60 \cdot \beta_{\text{RS3}}) \cdot (1.0 - \kappa_{\text{fiber}})$$
   wherein $\text{GI}$ is the Glycemic Index, and $\kappa_{\text{fiber}}$ is a mucosal diffusion resistance coefficient proportional to soluble dietary fiber mass.

5. The system as claimed in claim 1, wherein said physical wearable device further comprises an acoustic transducer and an inertial chew-detection module configured to filter wrist and jaw acceleration within a human mastication frequency band between $1.2\text{ Hz}$ and $2.5\text{ Hz}$, and autonomously trigger execution of said ODE digital twin engine upon detecting repetitive mastication cycles exceeding 180 seconds.

6. The system as claimed in claim 1, wherein said autonomous biofeedback ambulation controller computes said surplus circulating glucose mass $m_{\text{excess}}$ by integrating the positive area under the simulated postprandial curve above said clinical threshold:
   $$\text{AUC}_{\text{excess}} = \int_{0}^{240} \max(0, G(t) - G_{\text{threshold}}) \, dt$$
   $$m_{\text{excess}} = \frac{\text{AUC}_{\text{excess}} \cdot V_G \cdot BW}{1000 \cdot \tau_{\text{clearance}}}$$
   wherein $V_G$ is distribution volume, $BW$ is body weight in kilograms, and $\tau_{\text{clearance}}$ is a systemic vascular clearance time constant.

7. The system as claimed in claim 6, wherein said autonomous biofeedback ambulation controller translates said surplus glucose mass $m_{\text{excess}}$ into target physical walking minutes and step counts according to:
   $$\text{WalkMinutes} = \text{round}\left(\frac{m_{\text{excess}}}{0.38} \times 1.35\right)$$
   $$\text{TargetSteps} = \text{WalkMinutes} \times 110$$
   wherein $0.38\text{ g/min}$ represents the skeletal muscle GLUT-4 glucose clearance rate during brisk ambulation, and $1.35$ represents an endogenous hepatic compensation factor.

8. The system as claimed in claim 1, wherein said ambulation controller schedules an ambulation start time $t_{\text{start}} = \max\left(20, t_{\text{peak}} - 20\right)$ minutes post-meal, such that mechanical skeletal muscle contraction commences prior to the peak rate of glucose entry into systemic circulation.

9. The system as claimed in claim 1, further comprising an Ayushman Bharat Digital Mission (ABDM) national health gateway interface configured to ingest authenticated HL7 FHIR R4 DiagnosticReports and LOINC vital observations under a verified 14-digit ABHA identity, and dynamically calibrate baseline distribution volume $V_G$ and dynamic insulin sensitivity $S_I$ within said multi-compartment ODE digital twin engine.

10. The system as claimed in claim 1, further comprising calculating time-domain Heart Rate Variability (HRV) metrics comprising Root Mean Square of Successive Differences (RMSSD) and Baevsky Stress Index, and modulating hepatic glucose production within said ODE solver based upon sympathetic autonomic tone.

11. The system as claimed in claim 3, wherein gastric emptying within said ODE solver is retarded by a non-linear hyperbolic tangent function of ingested lipid mass:
    $$k_{\text{empt}}(t) = k_{\text{empt0}} \cdot \left[1.0 + 0.35 \cdot \tanh\left(\frac{M_{\text{fat}}}{25.0}\right)\right]^{-1}$$

12. The system as claimed in claim 1, further comprising generating a 3-phase pre-bite food sequencing protocol comprising:
    * Phase 1: Ingestion of viscous soluble and insoluble fiber at $t = 0\text{ minutes}$ to coat intestinal villi;
    * Phase 2: Ingestion of protein and lipids at $t = 10\text{ minutes}$ to stimulate endogenous glucagon-like peptide-1 (GLP-1) and cholecystokinin secretion; and
    * Phase 3: Ingestion of digestible carbohydrates at $t = 20\text{ minutes}$.

13. A physical wearable metabolic feedback apparatus comprising:
    * a multi-wavelength optical sensor (101) configured to record arterial photoplethysmography pulses;
    * a 3-axis accelerometer (103) configured to detect ambulatory steps and acoustic mastication vibrations;
    * a microcontroller coupled to a wireless transceiver (106); and
    * memory storing instructions that, when executed, cause the microcontroller to:
      * compute pulse transit times from ventricular depolarization to peripheral pulse arrival;
      * transmit said pulse transit times and step counts to an ODE metabolic digital twin solver;
      * receive an ambulation prescription comprising a target step count derived from surplus postprandial glucose mass; and
      * activate a physical haptic actuator upon local sensor verification that said target step count has been completed.

14. The apparatus as claimed in claim 13, wherein said microcontroller evaluates instantaneous step cadence, and issues a cadence acceleration alert if ambulatory cadence falls below $95\text{ steps/minute}$ during an active postprandial ambulation window.

15. The apparatus as claimed in claim 13, wherein said apparatus executes a local zero-crossing density algorithm on accelerometer telemetry to classify jaw movements into chew events and confirm meal ingestion.

---

### 11. ABSTRACT OF THE INVENTION
A biophysical simulation system and wearable sensor apparatus are disclosed for real-time metabolic digital twin forecasting and closed-loop physical ambulation control. The apparatus includes multi-wavelength optical PPG sensors (101), an accelerometer (103), and a wireless transceiver (106). A hemodynamic estimation engine computes arterial Pulse Transit Time (PTT) and derives continuous cuffless blood pressure via calibrated differential Hughes elasticity. An acoustic/inertial classifier identifies meal-start events from mastication frequencies ($1.2\text{ to }2.5\text{ Hz}$). The system interfaces with the Ayushman Bharat Digital Mission (ABDM) to calibrate physiological baseline parameters via authenticated HL7 FHIR R4 DiagnosticReports. A 7-compartment Runge-Kutta fourth-order ODE solver models glucose transport $G(t)$ by dynamically damping starch absorption $k_{\text{abs}}$ based on amylose linear chains and retrograded resistant starch (RS3) crystal structures. When projected glucose exceeds a clinical threshold ($>140\text{ mg/dL}$), an autonomous biofeedback controller computes the surplus circulating glucose mass $m_{\text{excess}}$ and prescribes an exact step count ($\approx 110\text{ steps/min}$) to clear excess glucose via insulin-independent skeletal muscle GLUT-4 translocation. Wearable step streams confirm metabolic restoration in a closed loop. The invention complies with Section 3(k) by executing physical sensor transformations and mechanical physiological work.

---
*(Dated this 9th day of November, 2026)*

**For BioSync AI Systems India Private Limited**
*(Patent Agent for the Applicant)*
